Avalon GloboCare (NASDAQ:ALBT) Stock Price Down 7.2% – Here’s What Happened

Avalon GloboCare Corp. (NASDAQ:ALBT) was down 7.2% during trading on Tuesday . The stock traded as low as $0.4850 and last traded at $0.5013. Approximately 179,305 shares were traded during mid-day trading, a decline of 12% from the average daily volume of 202,606 shares. The stock had previously closed at $0.54.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Avalon GloboCare in a report on Wednesday, January 21st. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Avalon GloboCare presently has an average rating of “Sell”.

Avalon GloboCare Trading Down 7.2%

The company’s 50-day moving average is $0.97 and its two-hundred day moving average is $1.68. The stock has a market capitalization of $2.13 million, a P/E ratio of -0.14 and a beta of -0.06.

Avalon GloboCare Company Profile

Avalon GloboCare is a clinical-stage biopharmaceutical company specializing in the research, development and commercialization of next-generation cell-based therapies and exosome-based diagnostics. The company’s pipeline focuses on allogeneic chimeric antigen receptor T-cell (CAR-T) and CAR-natural killer (CAR-NK) programs targeting hematological malignancies and solid tumors, alongside proprietary exosome platforms for noninvasive cancer detection.

Through its R&D facilities in both the United States and China, Avalon GloboCare integrates cell engineering, genetic modification and biomarker discovery to advance therapeutic and diagnostic candidates from preclinical research into human studies.